Market Place
Sourcing Support
Relief Announces Results of RLF-TD011 in Epidermolysis Bullosa
11 Nov 2024 //
ACCESSWIRE
US biotech finds Relief via reverse merger
04 Nov 2024 //
FIERCE BIOTECH
Relief Therapeutics Publishes Summary on PKU GOLIKE
29 Oct 2024 //
ACCESSWIRE
Relief Therapeutics Reports Study Results for RLF-OD032
25 Oct 2024 //
ACCESSWIRE
Relief Secures Patent for RLF-TD011 in Epidermolysis Bullosa
21 Oct 2024 //
ACCESSWIRE
Relief Therapeutics Announces Promising Results. RLF-TD011 trial.
08 Oct 2024 //
ACCESSWIRE
Relief Reports Positive Results For Phenylketonuria Study
04 Oct 2024 //
ACCESSWIRE
Relief Therapeutics Receives $2M Milestone Payment
23 Sep 2024 //
CONTRACT PHARMA
Relief Therapeutics Announces $2 Million Milestone
20 Sep 2024 //
ACCESSWIRE
Relief Therapeutics Completes Clinical Phase In RLF-OD032 Study
18 Sep 2024 //
ACCESSWIRE
Relief Therapeutics Presents PKU GOLIKE Study Results At SSIEM 2024
02 Sep 2024 //
ACCESSWIRE
Relief Therapeutics Reports H1 2024 Financial Results And Corporate Update
30 Aug 2024 //
ACCESSWIRE
Relief Therapeutics Secures up to $11 Million from Royalty Sales
05 Aug 2024 //
ACCESSWIRE
RELIEF THERAPEUTICS Holding SA Announces Results of Annual General Meeting
27 Jun 2024 //
ACCESSWIRE
Relief Therapeutics Announces Executive Change
03 Jun 2024 //
ACCESSWIRE
Relief Therapeutics Announces Notice of Annual General Meeting of Shareholders
30 May 2024 //
ACCESSWIRE
Relief Therapeutics Strengthens Leadership For Pipeline
08 May 2024 //
ACCESSWIRE
Relief Therapeutics has Published its Annual Report
30 Apr 2024 //
ACCESSWIRE
Relief Thera Holding Sa Announces Results of Extraordinary General Meeting
26 Apr 2024 //
ACCESSWIRE
RELIEF THERAPEUTICS Holding SA to Hold Extraordinary General Meeting
27 Mar 2024 //
ACCESSWIRE
Relief Enters into Exclusive License Agreement with Eton for PKU GOLIKE
22 Mar 2024 //
ACCESSWIRE
Relief Therapeutics Announces CEO Transition
22 Nov 2023 //
ACCESSWIRE
Relief Therapeutics Announces that 400,000 of its ADRs are Currently Outstanding
10 Oct 2023 //
ACCESSWIRE
Relief Therapeutics Reports Half-Year 2023 Financial Results
15 Sep 2023 //
ACCESSWIRE
Relief to Participate in the H.C. Wainwright 25th Annual Investment Conference
01 Sep 2023 //
ACCESSWIRE
Relief Announces New Exclusive Definitive Agreement for OLPRUVA(TM) (ACER-001)
30 Aug 2023 //
ACCESSWIRE
Relief Therapeutics Announces Extension of Distribution Agreement for PKU GOLIKE
19 Jul 2023 //
ACCESSWIRE
Relief Therapeutics & World Orphan Drug Alliance Announce an Exclusive Agreement
23 Jun 2023 //
ACCESSWIRE
RELIEF THERAPEUTICS Holding SA Announces Closing of CHF 5 M Private Placement
23 Jun 2023 //
ACCESSWIRE
RELIEF THERAPEUTICS Holding SA Announces CHF 5 Million Private Placement
16 Jun 2023 //
ACCESSWIRE
Relief Therapeutics Announces Notice of Annual General Meeting of Shareholders
26 May 2023 //
ACCESSWIRE
Relief Therapeutics Announces Swissmedic Approval and Operation of New Good mfg
15 May 2023 //
ACCESSWIRE
Relief Therapeutics Has Filed its 2022 Annual Report on Form 20-F
12 May 2023 //
ACCESSWIRE
Relief Announces Implementation Timeline for Reverse Split of Ordinary Shares
03 May 2023 //
BUSINESSWIRE
Relief Therapeutics Announces Collaboration Partner Reports OLPRUVA
01 May 2023 //
ACESSWIRE
Relief Announces Collaboration Partner Reports OLPRUVA™ Commercial Launch
01 May 2023 //
PHARMIWEB
Relief Announces Results of Extraordinary General Meeting of Shareholders
28 Apr 2023 //
ACCESSWIRE
Relief Therapeutics Announces Positive 12-Month Stability Data
17 Apr 2023 //
ACCESSWIRE
Relief Therapeutics Announces Full Year 2022 Financial Results
13 Apr 2023 //
ACCESSWIRE
Relief Therapeutics Announces Executive Leadership Team Change
05 Apr 2023 //
ACCESSWIRE
Relief Therapeutics to Hold Extraordinary General Meeting of Shareholders
04 Apr 2023 //
ACCESSWIRE
Relief Announces Results Identifying Preferred Urea Cycle Disorder Treatment
22 Mar 2023 //
ACCESSWIRE
Relief to Present Evidence for Improved Amino Acid Utilization with PKU GOLIKE
17 Mar 2023 //
ACCESSWIRE
Relief Therapeutics Announces Availability of New PKU GOLIKE BARs in Europe
16 Mar 2023 //
ACCESSWIRE
Relief Therapeutics Provides Update From Collaboration Partner on OLPRUVA
15 Mar 2023 //
ACCESSWIRE
Relief Announces U.S. Availability of New PKU GOLIKE Bars
28 Feb 2023 //
ACCESSWIRE
Relief Announces Enrollment of Three Patients in Trial of RLF-TD011
14 Feb 2023 //
ACCESSWIRE
Relief Therapeutics Provides an Update on its Financing Strategy
08 Feb 2023 //
ACCESSWIRE
Acer, Relief win FDA approval for rare disease after clearing inspection
28 Dec 2022 //
ENDPTS
Relief Therapeutics & NRx Announce Close of Definitive Settlement Agreements
20 Dec 2022 //
ACCESSWIRE
Relief Therapeutics to Participate in January Investor Meetings
14 Dec 2022 //
ACCESSWIRE
Relief Therapeutics Announces Issuance of Shares from Authorized Capital
13 Dec 2022 //
ACCESSWIRE
Relief Therapeutics Announces Executive Leadership Team Changes
08 Dec 2022 //
ACCESSWIRE
Relief Files Amendment No. 1 to its Registration Statement on Form F-1
16 Nov 2022 //
ACCESSWIRE
Relief Therapeutics, NRx Pharma enter definitive settlement agreements
15 Nov 2022 //
PHARMABIZ
Relief and NRx Pharmaceuticals Announce Execution of Settlement Agreements
14 Nov 2022 //
PRNEWSWIRE
Relief Therapeutics &NRx Pharma Further Extend their Stay of Pending Litigation
08 Nov 2022 //
ACCESSWIRE
Relief Announces Six-Month Stability Data on a New Formulation of RLF-100
07 Nov 2022 //
ACCESSWIRE
Aytu BioPharma to Report First Q Fiscal 2023 Financial Results on Nov 14, 2022
07 Nov 2022 //
ACCESSWIRE
RELIEF THERAPEUTICS Holding SA and NRx Extend Their Stay of Pending Litigation
26 Oct 2022 //
ACCESSWIRE
